MDWD MediWound Ltd. Stock Quote

MDWD [NASD]

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	39.63%	Shs Outstand	33.14M	Perf Week	-20.57%
Market Cap	44.70M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	0.00%	Shs Float	20.01M	Perf Month	-32.52%
Income	-15.40M	PEG	-	EPS next Q	-0.10	Inst Own	9.20%	Short Float	0.39%	Perf Quarter	-23.63%
Sales	20.90M	P/S	2.14	EPS this Y	-45.90%	Inst Trans	10.66%	Short Ratio	0.65	Perf Half Y	-29.08%
Book/sh	-0.07	P/B	-	EPS next Y	48.90%	ROA	-68.40%	Target Price	6.33	Perf Year	-60.51%
Cash/sh	0.32	P/C	4.38	EPS next 5Y	-	ROE	-	52W Range	1.21 - 4.01	Perf YTD	-41.10%
Dividend	-	P/FCF	-	EPS past 5Y	10.50%	ROI	432.60%	52W High	-65.34%	Beta	1.06
Dividend %	-	Quick Ratio	1.40	Sales past 5Y	72.50%	Gross Margin	31.40%	52W Low	14.88%	ATR	0.13
Employees	77	Current Ratio	1.60	Sales Q/Q	-23.00%	Oper. Margin	-63.50%	RSI (14)	26.55	Volatility	8.28% 6.81%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-11.90%	Profit Margin	-73.80%	Rel Volume	0.60	Prev Close	1.37
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 09 BMO	Payout	-	Avg Volume	120.64K	Price	1.39
Recom	1.70	SMA20	-21.48%	SMA50	-24.17%	SMA200	-31.66%	Volume	72,515	Change	1.46%

Jul-18-22

Resumed

Oppenheimer

Outperform

Sep-23-20

Initiated

BTIG Research

Buy

Nov-28-16

Initiated

Aegis Capital

Buy

$11

Aug-17-16

Initiated

Wells Fargo

Outperform

Apr-16-14

Initiated

Oppenheimer

Outperform

$25

Sep-22-22 08:02AM	MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million GlobeNewswire -22.86%
Sep-20-22 07:00AM	EMA Accepts MediWounds Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns GlobeNewswire
Sep-12-22 08:00AM	MediWounds NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress GlobeNewswire
Aug-23-22 07:00AM	IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum Homi Shamir to its Board of Directors GlobeNewswire
Aug-15-22 06:08AM	Things Look Grim For MediWound Ltd. (NASDAQ:MDWD) After Today's Downgrade Simply Wall St. +5.71%
08:45AM	Loading…
Aug-09-22 08:45AM	MediWound (MDWD) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:30AM	MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates GlobeNewswire
Aug-08-22 04:05PM	MediWound Enhances Its Board and Executive Leadership Team GlobeNewswire
Aug-03-22 07:30AM	MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns GlobeNewswire
Aug-02-22 10:00AM	MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Aug-01-22 08:00AM	MediWound Schedules Second Quarter 2022 Financial Results GlobeNewswire
Jul-11-22 11:12AM	MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial Benzinga
07:00AM	MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma GlobeNewswire
Jul-08-22 08:00AM	MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13 GlobeNewswire
Jul-07-22 09:19AM	MediWound's EscharEx Shows Safe, Effective, Rapid Debridement Of Leg Ulcers Benzinga
07:00AM	Loading…
07:00AM	MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers GlobeNewswire
Jul-05-22 04:05PM	MediWound to Host a Key Opinion Leader Investor Day on EscharEx GlobeNewswire
Jul-04-22 03:01PM	MediWound (NASDAQ:MDWD) shareholders are up 13% this past week, but still in the red over the last five years Simply Wall St.
Jun-30-22 07:00AM	MediWound Names Mr. Tzvi Palash as Chief Operating Officer GlobeNewswire
May-19-22 07:24AM	Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans? Simply Wall St.
May-17-22 08:15AM	MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates Zacks -6.35%
07:01AM	MediWound Announces CEO Transition GlobeNewswire
07:00AM	MediWound Reports First Quarter 2022 Financial Results GlobeNewswire
May-16-22 05:25PM	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates Zacks
May-12-22 07:33AM	MediWound Posts Promising EscharEx Data For Chronic Wounds Benzinga +6.11%
07:00AM	MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds GlobeNewswire
May-10-22 04:01PM	MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022 GlobeNewswire +7.43%
Apr-12-22 08:00AM	MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022 GlobeNewswire
Mar-29-22 08:00AM	MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022 GlobeNewswire +5.38%
Mar-22-22 04:05PM	MediWound Announces Exercise of Over-Allotment Option GlobeNewswire
07:30AM	Loading…
Mar-21-22 07:30AM	MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds GlobeNewswire
Mar-17-22 08:25AM	MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:00AM	MediWound Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Mar-16-22 05:45PM	Catalyst Pharmaceutical (CPRX) Q4 Earnings Lag Estimates Zacks
Mar-15-22 09:35AM	Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates Zacks
Mar-11-22 08:05AM	Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates Zacks
Mar-10-22 05:05PM	MediWound Announces Closing of Public Offering of Ordinary Shares GlobeNewswire
08:00AM	MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022 GlobeNewswire
Mar-09-22 10:00AM	MediWound (MDWD) Could Find Support Soon, Here's Why You Should Buy the Stock Now Zacks
Mar-03-22 08:30AM	MediWound Announces Pricing of Public Offering of Ordinary Shares GlobeNewswire -14.16%
Mar-02-22 04:24PM	MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares GlobeNewswire -6.22%
Mar-01-22 08:00AM	MediWound to Present at Upcoming Investor Conferences in March GlobeNewswire
Feb-17-22 03:02PM	Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline Zacks
06:00AM	MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army GlobeNewswire
Feb-14-22 09:03AM	MediWound to Present at Upcoming Investor Conferences in February GlobeNewswire
Feb-10-22 10:45AM	MediWound Receives Additional $9M From BARDA For NexoBrid FDA Application Resubmission Benzinga +5.02%
07:00AM	MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol GlobeNewswire
Jan-24-22 07:13AM	MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers Benzinga
06:00AM	MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds GlobeNewswire
Jan-20-22 07:15AM	Investors one-year losses grow to 51% as the stock sheds US$9.8m this past week Simply Wall St. -6.42%
Dec-20-21 07:00AM	MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds GlobeNewswire
Dec-06-21 07:00AM	MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study GlobeNewswire
Nov-18-21 07:30AM	EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid GlobeNewswire -7.74%
Nov-16-21 08:15AM	MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates Zacks -7.35%
07:00AM	MediWound Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-04-21 08:00AM	MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021 GlobeNewswire
Nov-02-21 03:02PM	Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-22-21 10:41AM	We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely Simply Wall St. -8.73%
Oct-04-21 07:30AM	MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care GlobeNewswire
Sep-03-21 04:14PM	MediWound to Present at Upcoming Investor Conferences GlobeNewswire
Aug-12-21 01:44AM	MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Aug-10-21 08:25AM	MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	MediWound Reports Second Quarter Financial Results GlobeNewswire
Aug-09-21 06:05AM	Would Shareholders Who Purchased MediWound's (NASDAQ:MDWD) Stock Five Years Be Happy With The Share price Today? Simply Wall St.
Aug-02-21 04:05PM	MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021 GlobeNewswire
Jul-29-21 03:05PM	Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-28-21 07:00AM	MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study GlobeNewswire
Jul-26-21 09:36AM	MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer Benzinga
07:00AM	MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma GlobeNewswire
Jul-20-21 08:18AM	MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients Benzinga
07:00AM	MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns GlobeNewswire
Jul-19-21 06:20AM	Bear of the Day: Vericel (VCEL) Zacks
Jul-18-21 10:45AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD PR Newswire
Jul-15-21 08:19PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD GlobeNewswire +8.94%
Jul-09-21 08:00AM	MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal GlobeNewswire +5.77%
Jul-07-21 08:21PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD GlobeNewswire
Jul-05-21 10:08PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD Newsfile
Jul-03-21 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD ACCESSWIRE
Jun-29-21 09:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD PR Newswire -27.84%
04:18PM	Why Vericel Tumbled by Nearly 15% on Tuesday Motley Fool
04:10PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of MediWound Ltd. (MDWD) Investigation ACCESSWIRE
09:23AM	FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop Benzinga
09:13AM	UPDATE 1-FDA declines to approve MediWound treatment for burns Reuters
08:45AM	MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application GlobeNewswire
Jun-18-21 10:48AM	Is Mediwound Ltd (MDWD) A Good Stock To Buy? Insider Monkey
Jun-09-21 04:30PM	MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study GlobeNewswire +8.11%
04:34AM	What Is The Ownership Structure Like For MediWound Ltd. (NASDAQ:MDWD)? Simply Wall St.
Jun-07-21 07:00AM	MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal GlobeNewswire
May-05-21 08:35AM	MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates Zacks -9.62%
07:00AM	MediWound Reports First Quarter 2021 Financial Results GlobeNewswire
06:45AM	MediWound Ltd. to Host Earnings Call ACCESSWIRE
Apr-28-21 12:33PM	Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-26-21 04:20PM	MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021 GlobeNewswire
Apr-22-21 07:30AM	MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx GlobeNewswire
Apr-02-21 03:54AM	Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth Simply Wall St.
Mar-24-21 04:05PM	MediWound Hosting Analyst Day Webinar on EscharEx Enzymatic Debridement Agent for Chronic Wounds GlobeNewswire -7.06%
Feb-25-21 04:01PM	MediWound to Participate in Upcoming March Investment Conferences GlobeNewswire -5.54%
07:00AM	MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire
06:30AM	MediWound Ltd. to Host Earnings Call ACCESSWIRE
Feb-22-21 06:30AM	MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer GlobeNewswire -9.63%

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience